NCT03968406 - Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2027

Conditions

Malignant Female Reproductive System NeoplasmRecurrent Cervical CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Vaginal CarcinomaStage IV Cervical Cancer AJCC v8Stage IV Fallopian Tube Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Primary Peritoneal Cancer AJCC v8Stage IV Uterine Corpus Cancer AJCC v8Stage IV Vaginal Cancer AJCC v8Stage IVA Cervical Cancer AJCC v8Stage IVA Fallopian Tube Cancer AJCC v8Stage IVA Ovarian Cancer AJCC v8Stage IVA Primary Peritoneal Cancer AJCC v8Stage IVA Uterine Corpus Cancer AJCC v8Stage IVA Vaginal Cancer AJCC v8Stage IVB Cervical Cancer AJCC v8Stage IVB Fallopian Tube Cancer AJCC v8Stage IVB Ovarian Cancer AJCC v8Stage IVB Primary Peritoneal Cancer AJCC v8Stage IVB Uterine Corpus Cancer AJCC v8Stage IVB Vaginal Cancer AJCC v8

Interventions

OTHER

Quality-of-Life Assessment

Ancillary studies

RADIATION

Radiation Therapy

Undergo radiation therapy

DRUG

Talazoparib

Given PO

Trial Locations (2)

21287

RECRUITING

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER